title: Long-term benefits of omalizumab in a patient with severe non-allergic asthma.
abstract: BACKGROUND
  Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy.
  
  
  METHODS
  We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile.
  
  
  CONCLUSIONS
  Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.
authors: Department of Respiratory Diseases, Santa Maria Nuova Hospital, Reggio, Emilia, Italy. menzella.francesco@asmn.re.it.
authors: Francesco
authors: F
authors: Menzella
authors: Roberto
authors: R
authors: Piro
authors: Nicola
authors: N
authors: Facciolongo
authors: Claudia
authors: C
authors: Castagnetti
authors: Anna
authors: A
authors: Simonazzi
authors: Luigi
authors: L
authors: Zucchi
references: Allergy. 2007 Feb;62(2):154-61
references: 17298424
references: Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003559
references: 16625585
references: Chest. 2011 Jan;139(1):28-35
references: 20688929
references: Respir Med. 2009 Nov;103(11):1633-42
references: 19619998
references: Clin Exp Allergy. 2005 Apr;35(4):408-16
references: 15836747
references: Br J Clin Pharmacol. 2007 May;63(5):548-61
references: 17096680
references: Am Rev Respir Dis. 1993 Apr;147(4):832-8
references: 8466117
references: J Allergy Clin Immunol. 1997 May;99(5):657-65
references: 9155833
references: J Immunol Methods. 2005 Aug;303(1-2):81-91
references: 16045925
references: Chest. 2011 Jan;139(1):190-3
references: 21208879
references: J Immunol. 1997 Feb 1;158(3):1438-45
references: 9013989
references: Allergy. 2005 Mar;60(3):309-16
references: 15679715
references: Eur Respir J. 2000 Oct;16(4):609-14
references: 11106200